Wall Street brokerages forecast that Nevro Corp (NYSE:NVRO) will announce $87.48 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Nevro’s earnings. The highest sales estimate is $88.61 million and the lowest is $85.88 million. Nevro reported sales of $87.64 million in the same quarter last year, which would suggest a negative year over year growth rate of 0.2%. The firm is scheduled to report its next earnings report on Monday, May 6th.

On average, analysts expect that Nevro will report full year sales of $405.47 million for the current financial year, with estimates ranging from $402.00 million to $407.98 million. For the next fiscal year, analysts anticipate that the business will report sales of $448.00 million, with estimates ranging from $431.90 million to $460.08 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Nevro.

Nevro (NYSE:NVRO) last posted its earnings results on Thursday, February 21st. The medical equipment provider reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.15). Nevro had a negative return on equity of 20.13% and a negative net margin of 12.70%. The business had revenue of $107.90 million for the quarter, compared to analyst estimates of $107.39 million. During the same period in the previous year, the firm posted ($0.15) earnings per share. The firm’s revenue was up 10.1% compared to the same quarter last year.

NVRO has been the topic of a number of research reports. Zacks Investment Research lowered Nevro from a “buy” rating to a “hold” rating in a report on Thursday, January 10th. Morgan Stanley raised Nevro from an “underweight” rating to an “overweight” rating and upped their price objective for the company from $41.00 to $70.00 in a report on Wednesday, March 20th. Wells Fargo & Co raised Nevro from a “market perform” rating to an “outperform” rating and set a $75.00 price objective on the stock in a report on Wednesday, March 20th. BMO Capital Markets raised Nevro from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $46.00 to $67.00 in a report on Tuesday, March 19th. Finally, Northland Securities reaffirmed a “hold” rating and issued a $48.00 price objective on shares of Nevro in a report on Friday, January 11th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $62.67.

NYSE NVRO traded down $0.11 on Thursday, reaching $65.58. The stock had a trading volume of 823,571 shares, compared to its average volume of 595,753. The company has a debt-to-equity ratio of 0.62, a current ratio of 7.11 and a quick ratio of 5.64. Nevro has a 1-year low of $34.75 and a 1-year high of $94.34. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -39.99 and a beta of 0.21.

Large investors have recently added to or reduced their stakes in the company. Advisor Group Inc. lifted its position in shares of Nevro by 64.5% during the 4th quarter. Advisor Group Inc. now owns 921 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 361 shares during the period. Oppenheimer Asset Management Inc. bought a new stake in shares of Nevro during the 4th quarter valued at $113,000. HRT Financial LLC bought a new stake in shares of Nevro during the 3rd quarter valued at $208,000. Tower Research Capital LLC TRC lifted its position in shares of Nevro by 4,723.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,341 shares of the medical equipment provider’s stock valued at $248,000 after acquiring an additional 4,251 shares during the period. Finally, Cerebellum GP LLC bought a new stake in shares of Nevro during the 4th quarter valued at $177,000.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Featured Story: Why is total return important?

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.